^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NILK-3301

    i
    Other names: NILK-3301
    Associations

    News

    Trials
    Company:
    LamKap Bio, Light Chain Biosci
    Drug class:
    CD28 stimulant, CEACAM5 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over2years
    Novel CEAxCD3 (NILK-2301) and CEAxCD28 (NILK-3301) κλ bispecific antibodies for next generation immunotherapy of CEA-expressing cancer (ESMO 2022)
    NILK-2301 + NILK-3301 combination treatment significantly increases activity already at low NILK-2301 doses with reduced cytokine release when given sequentially. IND-filing for NILK-2301 is expected in Q4/2022.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    CEACAM5 expression • IL2RA expression • CEACAM5 positive • CD4 expression
    |
    NILK-2301 • NILK-3301